ACURX PHARMACEUTICALS, LLC
259 Liberty Avenue

Staten Island, NY 10305

 

June 22, 2021

 

VIA EDGAR

 

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

 

Attention: Jane Park

       
  Re:   Acurx Pharmaceuticals, LLC
      Registration Statement on Form S-1
      File No. 333-256516
      Request for Acceleration

Dear Ms. Park:

 

Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, LLC (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-256516), so that it may become effective at 5:00 p.m. (Washington, D.C. time) on Thursday, June 24, 2021, or as soon thereafter as practicable.

 

Please call Ivan Blumenthal, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6784 with any comments or questions regarding this matter.

 

         
  Very truly yours,


Acurx Pharmaceuticals, LLC
 
 
  By:   /s/ David Luci  
    Name:   David Luci  
    Title:   President and Chief Executive Officer  
 

 

cc:Acurx Pharmaceuticals, LLC

David Luci

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Ivan K. Blumenthal, Esq.